Calcification of cardiovascular implants and diseased cardiovascular tissues is common'.
By definition, pathological calcification refers to the deposition of calcium phosphates or other calcific salts at sites which would not normally have become mineralized. Calcification of cardiovascular implants often results in clinical device failure due to mechanical dysfunction, vascular obstruction, or embolization of calcific deposits. At present, the pathogenesis of this disease process is incompletely understood and there are no satisfactory preventive measures or therapies to reverse cardiovascular implant calcification. This article, reviews and updates our growing understanding of cardiovascular implant calcification; it was stimulated by presentations and discussions in conjunction with the Conference on Cardiovascular Implant Calcification held as part of the 13th World Congress at the International Society for Heart Research at the University of Michigan, Ann Arbor, in May, 1989.
CLINICALLY IMPORTANT CARDIOVASCULAR CALCIFICATION
Calcific degeneration impairs the usefulness of a variety of clinical and experimental cardiovascular implants. Calcific degeneration of porcine bioprosthetic heart valves is their principal mode of failure, and calcification also impairs the durability of bovine pericardial bioprostheses'-4. Valved aortic homografts frequently develop calcification of both the aortic media and to a lesser extent the aortic valve leaflets; these calcific deposits may lead to functional compromise5, 6. Calcification is also important in causing functional compromise of other types of biological valve replacements, such as human dura mater or fascia lata valves'-3. Similarly, the use of trileaflet polymeric valves composed of various synthetic elastomers such as polytetrafluorethylene (Teflon) or polyurethane has been frustrated by calcification6-'. Calcification of synthetic vascular grafts occurs occasionally, but is rarely of clinical significance. Calcification of the flexing polymeric bladders of experimental ventricular assist devices and total artificial hearts is frequent and can cause failure of these devices"-"; however, mineralization of blood pumps in humans has not yet been reported, despite increasing implant durations. Dysfunction due to calcific degeneration of bioprosthetic heart valves has been the subject of clinicopathological studies, which in turn have stimulated experimental investigations (see later). Although heart valve bioprostheses fabricated from porcine aortic valve or bovine pericardium frequently fail a$ a result of calcific degeneration, bioprosthetic heart valve calcification occurs more rapidly in children and young adults than in the elderlylm4. As many as 50% of porcine aortic valve bioprostheses can be expected to fail by 1 O-l 5 yr post-operatively in adults, but after only 3 yr in dhildrenlm4 . ?he reasons for.age-dependent calcification are uncertain. Furthermore, patients with disordered calcium metabolism, as in renal disease, are also at an increased risk for bioprosthetic valve calcification. Pathological analyses of failed valves reveal dystrophic calcific deposits within the cusps which involve both cellular remnants and collagen fibrils (intrinsic mineralization)'-4. Calcific deposits are most extensive at regions of greatest haemodynamic stress, such as the commissures and annular attachments. Although bioprosthetic valve calcification causes either stenosis or regurgitation or both, regurgitation due to tearing at calcific deposits is most frequent, and calcific emboli can also occur. There is no satisfactory means short of re-operation for either treating this disorder once it occurs or preventing it. Valvuloplasty of native heart valves, particularly mitral valves, has met with some success' 3-1 5. However, balloon dilatation of calcified bioprosthetic valves has also resulted in significant, although incomplete, relief of calcific obstruction in some cases'6-20, but with significant risks of tearing and calcific emboli'8-20. These complications limit the safe use of this technique primarily to valves on the right side of the heart'8,20
EXPERIMENTAL MODELS
Calcification of implanted cardiovascular biomaterials has been studied through a variety of animal models (Table 7) , which are reviewed below. In general, animal models of cardiovascular implant calcification simulate human disease states in both morphological characteristics and pathophysiology.
Several unique model systems have become available; in particular, the pathology of mineralization of bioprosthetic heart valve tissue implanted subdermally in rats is comparable pathologically to that of human circulatory retrievals, despite having a different (non-circulatory) implant environment.
Biowosthetic tissue
Bioprosthetic heart valve calcification has been reproduced experimentally with subdermal implants in rats2"22, rabbits23, or mice24, and orthotopic or conduit-mounted valve replacements in large animals such as sheep25 or calves26. Both circulatory and non-circulatory bioprosthetic implants yield mineralization with morphological features comparable to those of clinical specimens. Investigations of bioprosthetic valve calcification using these animal models demonstrate that this disease process occurs as an interaction of host, implant and mechanical factors. This review emphasizes considerations of host and implant factors. The possible importance of mechanical factors in the mechanism of bioprosthetic calcification is less well understood, and the reader is referred to the limited basic research on this subject by others27-2g.
Younger animals calcify bioprosthetic valve implants more rapidly than do older subjects, thereby mimicking the clinical age dependence3'.
An increased serum phosphate level has been noted in younger animals and may, in part, explain this age effect3'. The most important implant factor identified is glutaraldehyde fixation30,3'; porcine aortic valves not pretreated with glutaraldehyde remain uncalcified in the rat subdermal model. Although glutaraldehyde probably serves to stabilize calcifiable structural components, Calcification of cells and cell fragments is due to a distortion of normal physiology. Normally, living mammalian cells maintain an intracellular calcium concentration which is approximately one ten-thousandth that of extracellular levels'-3. In physiological states, despite passive entry of calcium intocells through several types of calcium channels, this steep gradient is maintained by the outward pumping activity of several ATP-dependent calcium-ion exchange systems and intracellular calcium buffering mechanisms'-3. Cell death (necrosis) or dysfunction of diverse causes impairs the normal ability to expel intracellular calcium, while passive influx could not only continue to take place, but also would be accelerated due to membrane injury. Thus, cell necrosis or damage (including damage due to fixation with glutaraldehyde) causes both increased calcium influx (by not restricting calcium flow to specific channels) and decreased efflux (by impairing calcium exclusion mechanisms). The membranes of the cell serve as sites, rich in phosphorus, capable of reacting with exogenous calcium, in analogy to matrix vesicles. Thus, a net calcium influx, perhaps coupled with the activity of alkaline phosphatase, or other intracellular phosphatases leading to the hydrolysis of phosphoesters, is very likely the initiating mechanism of calcium phosphate crystallization in cardiovascular implants.
MECHANISMS OF CARDIOVASCULAR CALCIFICATION
Recently, alkaline phosphatase has been demonstrated histochemically within and on the surface membranes of devitalized cells of bovine pericardium both before and after glutaraldehyde fixation4*. Thus, alkaline phosphatase is not only intrinsic to this type of cardiovascular implant material but also is located at the sites where initial calcification occurs. Alkaline phosphatase has been hypothesized to facilitate the initiation of bone mineralization both by the hydrolysis of phosphoesters, thereby raising regional phosphate concentrations, and by the hydrolysis of inhibitors of ~aicificat~on, such as pyrophosphate. Recent investigations of the disease hypophosphatasia highlight the importance of alkaline phosphatase in skeletal minerali~ation4'. The lethal infantile form of hypophosphatasia is characterized by skeletal hypomineralization and calcium imbalance, with absence of circulating bone-type alkaline phosphatase activity, is due to a single base substitution in the genome for alkaline phosphatase4'. This missense mutation results in the synthesis of a dysfunctional enzyme molecule, thereby leading to the full-blown clinical syndrome.
Role of phospholipids
Acidic phospholipids such as phosphatidyl inositol and phosphatidyl serine are present at high levels in cells at the mineralizing front in bone and in pathological calcifications50.51. However, phospholipids and phosphoproteins form a nucleation complex with calcium and phosphate, which may initiate bone mineralization; such calciumphospholipid-phosphate complexes have been demonstrated in pathological calcification5*, 51. Detergent pretreatment of bioprosthetic heart valves, shown to inhibit mineralization (see later), likely acts bythe detergent-mediated extraction of phospholipids and other proteolipids, which takes place under these conditions.
Role of collagen and elastin
Structural protein mineralization occurs in both bioprosthetic heart valve and aortic homograft calcification. In animal model studies", ". 3o as well as clinical retrievals of bioprosthetic heart valves1-4, collagen-oriented calcification is usually noted to occur significantly later and perhaps secondary to cell-oriented calcific deposits. Calcification of collagen is prominent following long-term implantation. However, subdermal implants of Type I collagen sponges in rats also calcify 52 in the absence of cells devitalized by glutaraldehyde and this observation suggests that collagen calcification may occur independently of cell-oriented mineralization.
Elastin (in addition to cell-and collagen-associated) calcification is characteristically observed in the media of aortic homografts in rat subdermal explants, dog right ventricle to pulmonary artery grafts, and human clinical specimens38-44. Although limited pathological studies of aortic homograft calcification have been carried out, it is apparent that both cell-oriented and elastin calcification occur and that these phenomena may be mechanistically related4*, 53.
The calcium phosphate mineral phase
Poorly crystalline apatitic mineral resembling hydroxyapatite, the predominant minerat phase of bone, is present in a number of different cardiovascular calcifications3', 54, 55. However, other investigations have indicated less mature mineral phases, and thus suggest an orderly sequence leading to hydroxyapatite formation. In particular, octacalcium phosphate has been hypothesized to be a possible precursor to more mature mineral phases in a variety of clinical cardiovascular calcific deposits, including atherosclerotic plaque bioprosthetic valve calcification. Thus, calcium phosphate deposition proceeds from the formation of amorphous calcium phosphate, perhaps initiated by calcium phospholipid phosphate ~omplexation (see earlier), to the 
Aluminium chloride and ferric chloride
Observations that patients with renal failure treated with haemodialysis develop severe osteomalacia after trace-level exposure to A13+ suggested the strategy of pretreating bioprosthetic cusps with AICI, to prevent calcification68-70. The mechanism of action by which A13+ causes osteomalacia has been thought to result from an inhibition of hydroxyapatite crystal growth7'. FeCI, has also been associated, although in rare instances, with osteomalacia in cases of iron overload in renal insufficiency7'.
Recent studies demonstrate that preincubation of bioprosthetic tissue in FeCI, or AICI, prevents implant calcification without adverse effects3*. Morphological studies of bioprosthetic tissue pretreated with aluminum chloride reveal localization of both A13+ and Fe3+ to devitalized cells3*, 5g. Thus, A13+ and, perhaps Fe3+, may inhibit the membrane-linked calcification events at these important sites, which are the loci of the initial calcific deposits.
Other inhibitors
Phosphocitrate, an endogenous inhibitor of calcification, has been demonstrated to inhibit bioprosthetic tissue calcification (bovine pericardial) in the rat subdermal mode17*. However, this was only possible with local controlled release administration; systemic administration was not effective. The mechanism of action of phosphocitrate is incompletely understood. It is thought to act either by inhibiting hydroxyapatite nucleation or alkaline phosphatase or both7*. Protamine sulphate pretreatment of bioprosthetic tissue is another relatively recent and promising approach for preventing calcification as demonstrated by rat subdermal studies73. Covalent bonding o f rotamine to bioprosthetic p tissue is hypothesized to inhibit implant calcification due to its imparting a net positive surface charge, thereby repelling calcium.
FUTURE DIRECTIONS
Emerging areas of research may play an important role in the strategies necessary to understand and control cardiovascular implant calcification (Table 5 ). There is a need for calcification-resistant biomaterials, both tissue-derived biomaterials as well as synthetic elastomers such as polyurethane. In addition. preventive drug therapy may focus increasingly on implantable controlled release systems and immobilized drugs, since both of these approaches offer the possibility of optimizing local drug concentrations, while eliminating the possibility of side-effects which may be associated with systemic anticalcification therapy. If these 
